Cyclopeptide Utilizing Patents (Class 514/3.6)
-
Patent number: 11712459Abstract: The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).Type: GrantFiled: March 15, 2017Date of Patent: August 1, 2023Assignee: Cidara Therapeutics, Inc.Inventors: Kenneth Bartizal, Paul Daruwala, Jeffrey Brian Locke, Voon Ong, Taylor Sandison, Dirk Thye
-
Patent number: 11066447Abstract: In general, the invention relates to AbA derivatives that are useful for treating infection. These novel compounds are shown to be effective in treating various fungal infections. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various fungal infections.Type: GrantFiled: August 8, 2017Date of Patent: July 20, 2021Assignee: AueroGen Biosciences, Inc.Inventors: Peter Wuts, Ake P. Elhammer
-
Patent number: 9676821Abstract: The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.Type: GrantFiled: November 24, 2015Date of Patent: June 13, 2017Assignee: Cidara Therapeutics, Inc.Inventors: Kenneth Duke James, Jr., Christopher Patrick Laudeman, Navdeep Balkrishna Malkar, Balasingam Radhakrishnan
-
Patent number: 9139616Abstract: In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: wherein R1 is hydrogen or hydroxyl; wherein R2 is hydrogen or xylose; and wherein R3 and R4 are each hydrogen or together oxygen, or a pharmaceutically acceptable salt thereof; methods of isolating and purifying same; pharmaceutical compositions comprising same; agricultural compositions comprising same; and methods of treating and/or preventing fungal infections using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: July 17, 2014Date of Patent: September 22, 2015Assignee: University of Utah Research FoundationInventors: Eric W. Schmidt, Joseph O. Falkinham, Peter W. Jeffs
-
Publication number: 20150126436Abstract: The present invention provides a method of treatment of Scedosporium spp.Type: ApplicationFiled: May 13, 2013Publication date: May 7, 2015Applicant: BIODIEM LIMITEDInventors: Julie Phillips, Tania Sorrell, Sharon Chen
-
Patent number: 9023790Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified ?-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.Type: GrantFiled: June 24, 2011Date of Patent: May 5, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Susan K. Heimbecher, David Monteith, James D. Pipkin
-
Publication number: 20150087583Abstract: The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Applicant: Cidara Therapeutics, Inc.Inventors: Balasingam Radhakrishnan, Kenneth Duke James, JR., Anuradha Vaidya, Karen Polowy
-
Publication number: 20150080292Abstract: This invention provides new cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) that display very strong antifungal, antibacterial, antivirus activities in a variety of contexts in vitro; methods of making and using the compounds, wherein Locillomycin-A, Locillomycin-B and Locillomycin-C are derived and purified from the culture of Bacillus subtilis Bs916.Type: ApplicationFiled: February 26, 2014Publication date: March 19, 2015Inventor: Chuping Luo
-
Patent number: 8981048Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.Type: GrantFiled: November 10, 2011Date of Patent: March 17, 2015Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
-
Patent number: 8980827Abstract: The present invention provides a medicinal composition containing micafungin or a pharmaceutically acceptable salt thereof and trehalose as a stabilizing agent.Type: GrantFiled: January 31, 2012Date of Patent: March 17, 2015Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Yunhai Hong, Ying Xue, Xiaoming Ji
-
Publication number: 20150072923Abstract: The present invention relates to a composition comprising caspofungin or a pharmaceutical acceptable salt thereof and succinate or lactate as a buffering agent.Type: ApplicationFiled: November 19, 2014Publication date: March 12, 2015Inventors: Swapnil P. Shirode, Piyush Patel, Suresh Gidwani, Neil Parikh, Atul Patil, Anita Bevetek Mochnik
-
Publication number: 20150065417Abstract: Disclosed is a high purity cyclopeptide compound, the chemical structure of which is represented by formula (I). R represents H or a cation capable of forming a pharmaceutically acceptable salt, the purity being greater than or equal to 99.0%. Further disclosed are preparation method and use of the high purity cyclopeptide compound.Type: ApplicationFiled: March 29, 2013Publication date: March 5, 2015Inventors: Shidong Liu, Zhaoli Zhang, Xiusheng Wang, Xiao Zhang, Guangjun Jiao, Bingming He, Zhijun Tang, Xiaoming Ji
-
Patent number: 8969513Abstract: Disclosed are a caspofungin analog and applications thereof. The caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable salts thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of the compound.Type: GrantFiled: November 10, 2011Date of Patent: March 3, 2015Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
-
Publication number: 20150045290Abstract: Biosurfactants produced by a strain of Bacillus sp and to uses thereof. A composition comprising the biosurfactants, and a method for producing the biosurfactants. A method for obtaining a biosurfactant, and a device for implementing the method. The production of biopesticides or biosurfactants for the phytosanitary industry, and in the fields of the food, cosmetics, pharmaceutical and oil industries and the environment.Type: ApplicationFiled: October 3, 2012Publication date: February 12, 2015Applicant: Universite Lille 1-Sciences ET Technologies-USTLInventors: Francois Coutte, Philippe Jacques, Didier Lecouturier, Jean-Sebastien Guez, Pascal Dhulster, Valerie Leclere, Max Bechet
-
Patent number: 8951958Abstract: The present invention relates to a method for the purification of cyclopeptides of general formula (3) by means of a silicate.Type: GrantFiled: March 22, 2011Date of Patent: February 10, 2015Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.Inventor: Robertus Mattheus De Pater
-
Publication number: 20150030566Abstract: Compositions containing one or more tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives and analogues thereof, are described for controlling antimicrobial growth on plants, plant material or plant growth media, and methods for controlling or preventing the growth of microbial pathogens, and in particular fungal pathogens, on plants, plant parts and plant material are described herein. The active agents used to control these pathogens are tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives, analogues or modifications thereof.Type: ApplicationFiled: August 22, 2013Publication date: January 29, 2015Inventors: Marina Rautenbach, Abré De Beer, Anscha Mari Troskie, Johan Arnold Vosloo
-
Publication number: 20150024998Abstract: In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: wherein R1 is hydrogen or hydroxyl; wherein R2 is hydrogen, a-xylose or ?-xylose; and wherein R3 and R4 are each hydrogen or together oxygen, or a pharmaceutically acceptable salt thereof; methods of isolating and purifying same; pharmaceutical compositions comprising same; agricultural compositions comprising same; and methods of treating and/or preventing fungal infections using same. In one aspect, R2 is not hydrogen or ?-xylose when R1 is hydroxyl and R3 and R4 are together oxygen. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: December 20, 2012Publication date: January 22, 2015Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Eric W. Schmidt, Joseph O. Falkinham, Peter W. Jeffs
-
Publication number: 20150024997Abstract: The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.Type: ApplicationFiled: April 1, 2014Publication date: January 22, 2015Applicant: SEACHAID PHARMACEUTICALS, INC.Inventors: Kenneth Duke JAMES, JR., Christopher Patrick LAUDEMAN, Navdeep Balkrishna MALKAR, Balasingam RADHAKRISHNAN
-
Publication number: 20150018270Abstract: In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: wherein R1 is hydrogen or hydroxyl; wherein R2 is hydrogen or xylose; and wherein R3 and R4 are each hydrogen or together oxygen, or a pharmaceutically acceptable salt thereof; methods of isolating and purifying same; pharmaceutical compositions comprising same; agricultural compositions comprising same; and methods of treating and/or preventing fungal infections using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: July 17, 2014Publication date: January 15, 2015Inventors: Eric W. Schmidt, Joseph O. Falkinham, Peter W. Jeffs
-
Publication number: 20150011465Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.Type: ApplicationFiled: September 9, 2014Publication date: January 8, 2015Inventors: Kent Kirshenbaum, Sung Bin Shin
-
Patent number: 8906848Abstract: In general, the invention relates to methods of synthesizing AbA derivatives that are useful for treating infection and amenable to further chemical elaboration. These novel methods are scalable for industrial production and employ safer, simpler, and more efficient process conditions. Furthermore, the invention also provides novel compounds and intermediates useful for implementing the methods described herein and/or for the treatment of infection.Type: GrantFiled: March 23, 2012Date of Patent: December 9, 2014Assignee: AureoGen Biosciences, inc.Inventors: Peter Wuts, Ake P. Elhammer
-
Patent number: 8906866Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.Type: GrantFiled: March 15, 2013Date of Patent: December 9, 2014Assignees: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.Inventors: William V. Curran, Christopher M. Liu, Amy C. D. Bombardier, Richard A. Leese, You Seok Hwang, Blaise S. Lippa, Yanzhi Zhang
-
Patent number: 8889826Abstract: Disclosed herein are novel peptides and protected peptides. These compounds can be derived from naturally occurring peptides, such as those selected from colistin, circulin A, polymyxin A, polymyxin B, polymyxin D, octapeptin B, octapeptin C, and [Ile7]polymyxin B1. Also disclosed are pharmaceutical compositions containing the new peptides, as well as methods for preparing the novel peptides and protected peptides.Type: GrantFiled: July 1, 2005Date of Patent: November 18, 2014Assignee: BioSource Pharm, Inc.Inventors: Richard A. Leese, Noreen Francis, William V. Curran, Donald B. Borders, Howard Jarolmen
-
Publication number: 20140329741Abstract: The present application includes a method for improving human and animal health comprising administering an effective amount of a linus cyclopeptide (LCP) extract from flaxseed to a subject in need thereof. Also included are feeds, foodstuffs, functional food compositions, natural product compositions nutraceuticals and food additive compositions comprising an LCP extract from flaxseed.Type: ApplicationFiled: December 19, 2012Publication date: November 6, 2014Inventors: Bernard Laarveld, Andrew A. Olkowski
-
Publication number: 20140274882Abstract: Provided herein are methods for detecting an Aspergillus protease in a sample, diagnosing a subject with aspergillosis caused by an Aspergillus infection based on the presence of an Aspergillus protease in a sample, and methods of aspergillosis treatment that incorporate these diagnostic methods. In certain embodiments, the Aspergillus protease is Asp f2, and the Aspergillus infection is caused A. fumigatus, A. flavus, A. versicolor, A. niger, or A. terreus. Also provided herein are antibodies and kits for use in these methods, including novel antibodies specific for Asp f2.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Inventors: Markus KALKUM, Karine BAGRAMYAN, Diana DIAZ-AREVALO, James I. ITO, Sanjeet DADWAL
-
Publication number: 20140228280Abstract: Disclosed is a low impurity content caspofungin pharmaceutical composition, also disclosed is a method for preparing the low impurity content caspofungin pharmaceutical composition. The caspofungin pharmaceutical composition provided in the present invention is provided with great stability.Type: ApplicationFiled: September 25, 2012Publication date: August 14, 2014Applicant: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Yunhai Hong, Ying Xue, Lixin Sha, Xiaoming Ji
-
Publication number: 20140221274Abstract: Disclosed is a low impurity content caspofungin pharmaceutical composition, also disclosed is a method for preparing the low impurity content caspofungin pharmaceutical composition. The caspofungin pharmaceutical composition provided in the present invention is provided with great stability.Type: ApplicationFiled: September 25, 2012Publication date: August 7, 2014Inventors: Yunhai Hong, Ying Xue, Lixin Sha, Xiaoming Ji
-
Patent number: 8785376Abstract: In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: wherein R1 is hydrogen or hydroxyl; wherein R2 is hydrogen or xylose; and wherein R3 and R4 are each hydrogen or together oxygen, or a pharmaceutically acceptable salt thereof; methods of isolating and purifying same; pharmaceutical compositions comprising same; agricultural compositions comprising same; and methods of treating and/or preventing fungal infections using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 20, 2011Date of Patent: July 22, 2014Assignees: Virginia Tech Intellectual Properties, University of Utah Research FoundationInventors: Eric W. Schmidt, Joseph O. Falkinham, Peter W. Jeffs
-
Publication number: 20140142032Abstract: A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.Type: ApplicationFiled: December 21, 2012Publication date: May 22, 2014Inventors: Zhi-Qiang Jiang, Arunya Usayapant, David Bowman, Keith Kwok, Joel Peterson
-
Patent number: 8729224Abstract: Methods for use of a melanocortin receptor agonist cyclic peptide of the formula where R, x and y are as defined in the specification, and compositions and formulations including the peptide of the foregoing formula, for preventing, ameliorating or treating female sexual dysfunction.Type: GrantFiled: June 5, 2013Date of Patent: May 20, 2014Assignee: Palatin Technologies, Inc.Inventors: Yi-Qun Shi, Shubh D. Sharma, Wei Yang, Xin Chen
-
Patent number: 8722619Abstract: The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.Type: GrantFiled: May 3, 2013Date of Patent: May 13, 2014Assignee: Seachaid Pharmaceuticals, Inc.Inventors: Kenneth Duke James, Jr., Christopher Patrick Laudeman
-
Patent number: 8691756Abstract: The present application describes a method of treating a bacterial infection comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a defined macrocycle compound.Type: GrantFiled: May 23, 2013Date of Patent: April 8, 2014Assignee: Novartis AGInventors: Roger Aki Fujimoto, Philipp Krastel, Matthew J. LaMarche
-
Patent number: 8637451Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.Type: GrantFiled: December 29, 2011Date of Patent: January 28, 2014Assignee: Synergy Pharmaceuticals Inc.Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
-
Publication number: 20140024578Abstract: In general, the invention relates to methods of synthesizing AbA derivatives that are useful for treating infection and amenable to further chemical elaboration. These novel methods are scalable for industrial production and employ safer, simpler, and more efficient process conditions. Furthermore, the invention also provides novel compounds and intermediates useful for implementing the methods described herein and/or for the treatment of infection.Type: ApplicationFiled: March 23, 2012Publication date: January 23, 2014Applicant: AureoGen Biosciences ,Inc.Inventors: Peter Wuts, Ake P. Elhammer
-
Publication number: 20130338060Abstract: The present invention provides a liquid medicinal composition containing micafungin or a pharmaceutically acceptable salt thereof and a stabilizing agent.Type: ApplicationFiled: January 31, 2012Publication date: December 19, 2013Applicant: SHANGHAI TECHWELL BIOPHARMACEUTICAL CO., LTDInventors: Yunhai Hong, Ying Xue, Xiaoming Ji
-
Publication number: 20130331312Abstract: The present invention provides a medicinal composition containing micafungin or a pharmaceutically acceptable salt thereof and trehalose as a stabilizing agent.Type: ApplicationFiled: January 31, 2012Publication date: December 12, 2013Inventors: Yunhai Hong, Ying Xue, Xiaoming Ji
-
Patent number: 8598115Abstract: A compound useful as an antifungal agent, particularly a therapeutic agent for deep-seated mycoses, is provided. A fungus Acremonium persicinum was collected, and cyclic compounds were isolated from culture liquids thereof. The present inventors confirmed that the cyclic compounds or salts thereof have a potent antifungal activity and are useful as medicaments, particularly an antifungal agent, and thus the present invention was completed. The cyclic compound and the salt thereof according to the present invention can be used as an agent for preventing or treating mycoses, particularly deep-seated mycoses.Type: GrantFiled: March 13, 2009Date of Patent: December 3, 2013Assignee: Astellas Pharma Inc.Inventors: Ikuko Nakamura, Koji Yoshikawa, Keisuke Ohsumi, Ryuichi Kanasaki, Shigehiro Takase
-
Publication number: 20130296229Abstract: Disclosed are a caspofungin analog and applications thereof. Said caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable slats thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of said compound.Type: ApplicationFiled: November 10, 2011Publication date: November 7, 2013Applicant: SHANGHAM TECH-WELL BIOPHARMACEUTICAL CO., LTDInventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
-
Publication number: 20130288956Abstract: An object of the present invention is to provide a pharmaceutical composition having superior antifungal activity. The present invention provides a pharmaceutical composition comprising 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine or 2-amino-1-((phosphonooxy)methyl)-3-(3-((4-((2-pyridinyloxy)methyl)phenyl)methyl)-5-isoxazolyl)-pyridinium or a salt thereof in combination with an antifungal agent.Type: ApplicationFiled: November 4, 2011Publication date: October 31, 2013Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Naoaki Watanabe, Katsura Hata, Mamiko Miyazaki, Takaaki Horii
-
Patent number: 8551942Abstract: A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.Type: GrantFiled: September 27, 2012Date of Patent: October 8, 2013Assignee: Merck Sharp & Dohme, Corp.Inventors: Sachin Mittal, Hossain Jahansouz, Sutthilug Sottivirat
-
Publication number: 20130244930Abstract: The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicant: Seachaid Pharmaceuticals, Inc.Inventors: Kenneth Duke JAMES, JR., Christopher Patrick LAUDEMAN
-
Publication number: 20130225482Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.Type: ApplicationFiled: November 10, 2011Publication date: August 29, 2013Applicant: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
-
Publication number: 20130216609Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: March 21, 2013Publication date: August 22, 2013Applicants: The Regents of the University of California, Otonomy, Inc.Inventors: Otonomy, Inc., The Regents of the University of California
-
Patent number: 8513184Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.Type: GrantFiled: December 8, 2011Date of Patent: August 20, 2013Assignees: Gilead Sciences, Inc., Selcia LimitedInventors: Todd Appleby, Hans G. Fliri, Andrew J. Keats, Linos Lazarides, Richard L. Mackman, Simon N. Pettit, Karine G. Poullennec, Jonathan Sanvoisin, Victoria A. Steadman, Gregory M. Watt
-
Patent number: 8497348Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: GrantFiled: December 17, 2012Date of Patent: July 30, 2013Assignee: Synergy Pharmaceuticals Inc.Inventors: Kunwar Shailubhai, Gary S. Jacob
-
Patent number: 8487073Abstract: A melanocortin receptor agonist cyclic peptide of the formula where R, x and y are as defined in the specification, compositions and formulations including the peptide of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including sexual dysfunction such as male erectile dysfunction and female sexual dysfunction.Type: GrantFiled: November 23, 2010Date of Patent: July 16, 2013Assignee: Palatin Technologies, Inc.Inventors: Yi-Qun Shi, Shubh D. Sharma, Wei Yang, Xin Chen
-
Patent number: 8476224Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.Type: GrantFiled: June 3, 2008Date of Patent: July 2, 2013Assignee: Novartis AGInventors: Roger Aki Fujimoto, Philipp Krastel, Matthew J. Lamarche
-
Patent number: 8470783Abstract: A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.Type: GrantFiled: August 20, 2002Date of Patent: June 25, 2013Assignee: Astellas Pharma Inc.Inventors: Yuka Sasakawa, Yoshinori Naoe
-
Publication number: 20130096053Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified ?-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.Type: ApplicationFiled: June 24, 2011Publication date: April 18, 2013Applicant: Merck Sharp & Dohme Corp.Inventors: Susan K. Heimbecher, David Monteith
-
Publication number: 20130090284Abstract: In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: wherein R1 is hydrogen or hydroxyl; wherein R2 is hydrogen or xylose; and wherein R3 and R4 are each hydrogen or together oxygen, or a pharmaceutically acceptable salt thereof; methods of isolating and purifying same; pharmaceutical compositions comprising same; agricultural compositions comprising same; and methods of treating and/or preventing fungal infections using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: December 20, 2011Publication date: April 11, 2013Inventors: Eric W. Schmidt, Joseph O. Falkinham, Peter W. Jeffs